Alzheimer's Disease (AD), the most common cause of dementia in the elderly, is estimated to affect over 4 million Americans, a number projected to grow in the next few decades. Research progress has led to improved diagnostic accuracy for AD, the development of symptomatic medications, and provision of social and community care networks. However, current treatment options provide only temporary stabilization at best, and the overall cost for care of patients with AD in the USA exceeds $100 billion per year. Further research is essential to make progress in the fight against AD. The UCSD Alzheimer's Disease Research Center (ADRC) has contributed to much research progress in the past 25 years. In order to facilitate and conduct research into the causes, treatment and prevention of AD, the overall Specific Aims of this renewal application for the Center are: 1) To support research efforts by maintaining resources that include cohorts of subjects with normal cognition, AD and other dementias;neuropathology tissue from well-characterized subjects;biological samples and DMA;and to maintain a comprehensive database. 2) To coordinate pilot and research projects related to Alzheimer's Disease, aging or neurodegeneration. 3) To foster professional education and training, as well as educational outreach efforts in the community. 4) To collaborate with other ADCs, with NACC, and with national research efforts related to AD and dementia. The Center will consist of an Administrative Core, a Clinical Core (with a Hispanic Minority Satellite), a Neuropathology Core, a Data and Biostatistics Core, an Education and Information Core. Three research Projects are proposed: 1) Structural MRI analyses to distinguish patients with AD, Dementia with Lewy Bodies (DLB) and Controls. 2) Axonal transport of a-synuclein and the pathogenesis of DLB. 3) Psychometric prediction of the rate of progression of AD and DLB. Three Pilot Project awards will be issued each year. The Center will follow 500 subjects, using annual standard evaluations that include the Uniform Data Set components and will contribute to national research efforts by contributing data to the National Alzheimer's Coordinating Center, and to the Alzheimer's Disease Neuroimaging Initiative (ADNI). ADRC subjects will be offered participation in clinical trials organized by the Alzheimer's Disease Cooperative Study (ADCS) and by pharmaceutical companies. The Center will continue to support innovative research, to train new investigators, and to improve public knowledge and awareness about aging and AD, as well as to provide innovative support efforts for patients and families affected by AD.
AD affects millions of Americans with its risk growing exponentially with age. The AD Centers Program fosters research related to AD and non-AD dementias. The ADRC will enhance the performance of innovative research on AD and related topics, including research that may lead to potential disease modifying therapies or behavioral treatments. It will provide an environment and core resources to enhance research, foster professional and community training, and coordinate interdisciplinary research.
|Golde, Todd E; DeKosky, Steven T; Galasko, Douglas (2018) Alzheimer's disease: The right drug, the right time. Science 362:1250-1251|
|Young, Jessica E; Fong, Lauren K; Frankowski, Harald et al. (2018) Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. Stem Cell Reports 10:1046-1058|
|Reas, Emilie T; Hagler Jr, Donald J; White, Nathan S et al. (2018) Microstructural brain changes track cognitive decline in mild cognitive impairment. Neuroimage Clin 20:883-891|
|Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27|
|Graves, Lisa V; Holden, Heather M; Van Etten, Emily J et al. (2018) New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc 24:833-841|
|Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307|
|Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642|
|Fong, Lauren K; Yang, Max M; Dos Santos Chaves, Rodrigo et al. (2018) Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-? clearance in human astrocytes. J Biol Chem 293:11341-11357|
|Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18|
|Spencer, Brian; Brüschweiler, Sven; Sealey-Cardona, Marco et al. (2018) Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol 136:69-87|
Showing the most recent 10 out of 914 publications